SCHEMBL24035545

SCHEMBL24035545

CC1(C)Cc2c(C#N)cc(-c3cc(Cl)ncc3F)n2C1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CDK9 P50750 8/20 0.34
CCNT1 O60563 3/20 0.33
PLA2G7 Q13093 1/20 0.33
CCNK O75909 1/20 0.32
CDK1 P06493 1/20 0.32
CDK4 P11802 1/20 0.32
CCNB1 P14635 1/20 0.32
CCNE1 P24864 1/20 0.32
CDK2 P24941 1/20 0.32
CDK7 P50613 1/20 0.32
CCNH P51946 1/20 0.32
MNAT1 P51948 1/20 0.32
CDK3 Q00526 1/20 0.32
CDK6 Q00534 1/20 0.32
CDK5 Q00535 1/20 0.32
CDK12 Q9NYV4 1/20 0.32
TGFBR1 P36897 1/20 0.31
TLR9 Q9NR96 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25095187 0.83 CDK9 (0.38) KDM4EALDH1A1CDK9CCNT1PLA2G7
SCHEMBL24035549 0.81 CDK9 (0.35) KDM4EALDH1A1CDK9CCNT1CCNK
SCHEMBL30161765 0.74 CDK9 (0.69) CDK9CCNT1CCNKCDK1CDK4
SCHEMBL25095225 0.74 CDK9 (0.41) KDM4EALDH1A1CDK9CCNT1CCNK
SCHEMBL18338545 0.73 CDK9 (0.53) CDK9CCNT1CCNKCDK1CDK4
SCHEMBL30161780 0.73 CDK9 (0.73) CDK9CCNT1CCNKCDK1CDK4
SCHEMBL24035131 0.73 CDK9 (0.73) CDK9CCNT1CCNKCDK1CDK4
SCHEMBL28918421 0.71 CDK9 (0.54) CDK9CCNT1CCNKCDK1CDK4
SCHEMBL25635503 0.68 CDK9 (0.36) KDM4EALDH1A1CDK9CCNT1CCNK
SCHEMBL24035558 0.67 CDK9 (0.37) KDM4EALDH1A1CDK9CCNT1CCNK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192703-A1 Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof Suzhou Alphama Biotechnology Co., Ltd. (CN) 2023-06-22 US disclosed
US-20230192703-A1 Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof Suzhou Alphama Biotechnology Co., Ltd. (CN) 2023-06-22 US disclosed
US-20230192703-A1 Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof Suzhou Alphama Biotechnology Co., Ltd. (CN) 2023-06-22 US disclosed
EP-4141004-A1 POLYCYCLIC AMIDE DERIVATIVE AS CDK9 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF Suzhou Alphama Biotechnology Co., Ltd. (CN) 2023-03-01 EP disclosed
WO-2021227904-A1 POLYCYCLIC AMIDE DERIVATIVE AS CDK9 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 苏州阿尔脉生物科技有限公司 2021-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192703-A1 Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof CDK9, CDK8, CDK19 KDM4E 479/4885ALDH1A1 4012/4885CDK9 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.